India's specialty chemicals sector Q4 FY26 marks the end of the inventory correction cycle. Acutaas delivered record results (+33%), Epigral benefited from an ECU price spike, and Navin Fluorine showed CDMO recovery. Here is StockMirror's sector comparison.
Quick Comparison Table
| Company | Ticker | FY26 Revenue | EBITDA Margin | FY27 Theme | AI Signal |
|---|---|---|---|---|---|
| Acutaas Chemicals | ACUTAAS | ₹1,339 Cr (+33%) | ~35% | CDMO ₹1,000 Cr FY28 | Good/High |
| Navin Fluorine | NAVINFLUOR | Strong recovery | ~28%+ | CDMO + fluorination | Good/High |
| Epigral | EPIGRAL | ₹2,542 Cr FY26 | ~20-23% | ECU cycle + specialty | Good/Medium |
CDMO Leaders
Acutaas Chemicals — CDMO Scaling to ₹1,000 Cr
Acutaas Chemicals delivered landmark FY26 results: revenue ₹1,339 crore (+33%), EBITDA ₹480 crore (~35% margin), PAT ₹356 crore, net cash ₹198 crore. The centrepiece: CDMO revenue is scaling toward ₹1,000 crore by FY28. Q4 EBITDA margin expanded 1,487 bps YoY as semiconductor chemical demand recovered and CDMO mix improved. The Indichem JV (₹190 crore in battery and semiconductor chemicals) creates forward optionality.
Why Acutaas's CDMO strategy is credible: Existing customer relationships with global pharma/agro + technical synthesis capability + net cash balance sheet means no financing risk for expansion. StockMirror signal: Good/High — record FY26, CDMO scaling, semiconductor recovery, battery chemical optionality.
📊 Full Acutaas Q4 FY26 analysis →
Navin Fluorine — Fluorination Chemistry Leader
Navin Fluorine International is India's leading fluorine chemistry company — making fluorinated intermediates, agrochemical intermediates, and specialty fluorochemicals for global pharma and agro clients. FY26 showed CDMO recovery after FY25 inventory-led softness. Navin's moat is the same as in all specialty chemicals: fluorination chemistry is technically complex, requires specialized handling, and few companies globally have the capability at Navin's scale.
The Navin thesis: Fluorination chemistry + CDMO expertise = pricing power in a segment where there are fewer than 20 global competitors. As pharma R&D and agro chemical discovery activity increases, Navin's CDMO pipeline grows. StockMirror signal: Good/High — fluorination moat; CDMO recovery; long-term structural demand.
📊 Full Navin Fluorine Q4 FY26 analysis →
Chlor-Alkali and Commodity Specialty
Epigral — ECU Price Spike Beneficiary
Epigral (chlor-alkali: chlorine, caustic soda) reported Q4 record revenue of ₹736 crore (+22% QoQ) as ECU prices spiked to ₹37,000/MT from ₹30,000. FY26 revenue ₹2,542 crore with net debt ₹508 crore. FY27 guidance: 10-12% volume growth — conservative guidance as ECU price sustainability is uncertain. The business serves PVC, paper, textiles, and water treatment industries.
The Epigral caution: Chlor-alkali is more commodity than specialty — ECU prices are market-determined and can reverse. The EBITDA margin improvement (23% in Q4) is partly ECU-linked. Long-term thesis requires Epigral moving downstream into value-added chlorine derivatives. StockMirror signal: Good/Medium — ECU spike beneficiary; volume growth guided; commodity price cycle risk.
📊 Full Epigral Q4 FY26 analysis →
Key Themes: India Specialty Chemicals Q4 FY26
1. Inventory Destocking Is Over — Fresh Demand Returning
The 18-month inventory correction cycle (FY24-FY25) that hit India's specialty chemical sector is largely over. Global buyers had overstocked during COVID supply chain panic; by Q4 FY26 the drawdown is complete and fresh procurement is returning. Acutaas's 33% FY26 growth and Navin Fluorine's CDMO recovery both confirm this. FY27 should see the full benefit of the demand recovery.
2. CDMO Is the Premium Segment — Building Multi-Year Revenue Streams
Acutaas (₹1,000 crore CDMO FY28 target), Navin Fluorine (CDMO ramp), and Divi's Laboratories (not in this comparison) are all building CDMO capacity because: (1) CDMO margins are 40-50% vs 25-35% for standard specialty, (2) long-term contracts create revenue visibility, (3) China+1 CDMO qualification is accelerating as pharma companies want supply chain resilience.
3. China+1 — India Is the Prime Beneficiary
US and European pharma and agro companies are qualifying Indian CDMO providers as backup or primary sources for complex molecule synthesis. India has the regulatory approvals (USFDA, REACH), technical talent, and cost advantage. This is a 5-10 year trend — CDMO revenues at Indian companies will compound over this period.
4. Commodity vs Specialty Differentiation Matters
Epigral (chlor-alkali) faces commodity ECU price cycles. Acutaas and Navin Fluorine (specialty chemistry, CDMO) have structural pricing power. Investors should not treat all "specialty chemical" companies the same — the distinction between commodity-adjacent (chlor-alkali, PVC intermediates) and true specialty (fluorination, custom synthesis) is critical for margin sustainability analysis.
StockMirror's FY27 Specialty Chemicals Framework
| Segment | FY27 View | Best Positioned |
|---|---|---|
| CDMO — pharma synthesis | Strong; China+1 driving contracts | Acutaas, Navin Fluorine |
| Fluorine chemistry | Recovering; agro/pharma demand | Navin Fluorine |
| Chlor-alkali | ECU price dependent; volume growing | Epigral (ECU watch) |
| Battery chemicals | Early stage; FY28-FY30 payoff | Acutaas (Indichem JV) |
Track all specialty chemicals earnings with full AI management signals: Acutaas · Navin Fluorine · Epigral
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StockMirror's AI analysis is based on publicly available earnings transcripts and BSE/NSE filings. Please consult a SEBI-registered financial advisor before making investment decisions.